Horizon Discovery Group plc Director/PDMR Shareholding (4032P)
February 07 2019 - 6:22AM
UK Regulatory
TIDMHZD
RNS Number : 4032P
Horizon Discovery Group plc
07 February 2019
Horizon Discovery Group plc
7 February 2019
Horizon Discovery Group plc
Director/PDMR Shareholding
Cambridge, UK, 7 February 2019: Horizon Discovery Group plc
(LSE: HZD) ("Horizon", "the Group" or "the Company"), a global
leader in gene editing and gene modulation technologies, announces
that the following options were granted on 6 February 2019 over the
Company's ordinary shares of 1 pence each ("Ordinary Shares") to
Jayesh Pankhania, CFO, in accordance with the Company's Long Term
Incentive Plan:
Director Number of Ordinary Exercise price per
Shares over which share
options granted
Jayesh Pankhania 45,064 GBP0.01
------------------- -------------------
Jayesh Pankhania 128,755 GBP1.7475
------------------- -------------------
The options with a GBP0.01 exercise price will vest equally on
each of the second, third and fourth anniversaries of the grant
date.
The options with a GBP1.7475 exercise price will vest 25% on the
third anniversary of the grant date, 25% on the fourth anniversary
of the grant date and 50% on the fifth anniversary of the grant
date.
The options granted are equivalent to 0.116% of the Company's
existing issued share capital.
ENDS
For further information from Horizon Discovery Group plc, please
contact:
Horizon Discovery Group plc
Terry Pizzie, Chief Executive Officer
Jayesh Pankhania, Chief Financial Officer
Tel: +44 (0) 1223 655 580
Numis Securities Limited (Broker and NOMAD)
Michael Meade / Freddie Barnfield / Duncan Monteith
Tel: +44 (0) 207 260 1000
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Matthew Neal / Melissa Gardiner
Tel: +44 (0) 20 3709 5700
Email: horizon@consilium-comms.com
About Horizon Discovery Group plc www.horizondiscovery.com
Horizon Discovery Group plc (LSE: HZD) ("Horizon") is a world
leader in gene editing and gene modulation technologies. Horizon
designs and engineers cells using its translational genomics
platform, a highly precise and flexible suite of DNA editing tools
(rAAV, ZFN, CRISPR and Transposon) and, following the acquisition
of Dharmacon, Inc., its functional genomics platform comprising
gene knockdown (RNAi) and gene expression (cDNA, ORF) tools, for
research and clinical applications that advance human health.
Horizon's platforms and capabilities enable researchers to alter
almost any gene or modulate its function in human or mammalian
cell-lines.
Horizon offers an extensive range of catalogue products and
related research services to support a greater understanding of the
function of genes across all species and the genetic drivers of
human disease and the development of personalised molecular, cell
and gene therapies. These have been adopted by over 10,000
academic, drug discovery, drug manufacturing and clinical
diagnostics customers around the globe, as well as in the Company's
own R&D pipeline.
Horizon is headquartered in Cambridge, UK, and is listed on the
London Stock Exchange's AIM market under the ticker "HZD".
1 Details of the person discharging managerial responsibilities/person
closely associated
a) Name Jayesh Pankhania
-------------------------------------- -----------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position/status Chief Financial Officer - PDMR
-------------------------------------- -----------------------------------
b) Initial notification /Amendment Initial Notification
-------------------------------------- -----------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name Horizon Discovery Group plc
-------------------------------------- -----------------------------------
b) Legal Entity Identifier 213800L812B9NI5M3G89
-------------------------------------- -----------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------------
a) Description of the financial Options over ordinary shares
instrument, type of instrument of 1.0 pence each
Identification code
GB00BK8FL363
-------------------------------------- -----------------------------------
b) Nature of the transaction Grant of Options
-------------------------------------- -----------------------------------
c) Currency GBP
-------------------------------------- -----------------------------------
d) Price(s) and volume(s) Exercise Price No. of shares
-------------------------------------- ------------------ ---------------
GBP0.01 45,064
-------------------------------------------------------------- ---------------
GBP1.7475 128,755
-------------------------------------------------------------- ---------------
e) Aggregated information
- Aggregated volume
- Price n/a
- Aggregated total
-------------------------------------- -----------------------------------
f) Date of the transaction 6 February 2019
-------------------------------------- -----------------------------------
g) Place of the transaction Off market
-------------------------------------- -----------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHLDLFBKLFLBBB
(END) Dow Jones Newswires
February 07, 2019 07:22 ET (12:22 GMT)
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From Apr 2024 to May 2024
Horizon Discovery (LSE:HZD)
Historical Stock Chart
From May 2023 to May 2024